Business Description
Genenta Science SPA
NAICS : 325412
SIC : 2834
ISIN : US36870W1009
Share Class Description:
STU:K5F: ADRDescription
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.91 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -19.3 | |||||
| 3-Year EPS without NRI Growth Rate | -18.3 | |||||
| 3-Year FCF Growth Rate | -14.4 | |||||
| 3-Year Book Growth Rate | 3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.99 | |||||
| 9-Day RSI | 43.19 | |||||
| 14-Day RSI | 44.63 | |||||
| 6-1 Month Momentum % | -26.36 | |||||
| 12-1 Month Momentum % | -38.87 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 12.24 | |||||
| Quick Ratio | 12.24 | |||||
| Cash Ratio | 10.82 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.2 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -45.74 | |||||
| ROA % | -42.34 | |||||
| ROIC % | -498.64 | |||||
| ROC (Joel Greenblatt) % | -11811.74 | |||||
| ROCE % | -45.82 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.6 | |||||
| Price-to-Tangible-Book | 2.62 | |||||
| EV-to-EBIT | -3.14 | |||||
| EV-to-Forward-EBIT | -1.94 | |||||
| EV-to-EBITDA | -3.15 | |||||
| EV-to-Forward-EBITDA | -1.94 | |||||
| EV-to-Forward-Revenue | 14.02 | |||||
| EV-to-FCF | -3.28 | |||||
| Price-to-Net-Current-Asset-Value | 2.75 | |||||
| Price-to-Net-Cash | 3.13 | |||||
| Earnings Yield (Greenblatt) % | -31.85 | |||||
| FCF Yield % | -20.18 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Genenta Science SPA Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.64 | ||
| Beta | 0 | ||
| Volatility % | 26.75 | ||
| 14-Day RSI | 44.63 | ||
| 14-Day ATR (€) | 0.180708 | ||
| 20-Day SMA (€) | 2.861 | ||
| 12-1 Month Momentum % | -38.87 | ||
| 52-Week Range (€) | 2.26 - 5.9 | ||
| Shares Outstanding (Mil) | 18.22 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Genenta Science SPA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Genenta Science SPA Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Genenta Science SPA Frequently Asked Questions
What is Genenta Science SPA(STU:K5F)'s stock price today?
The current price of STU:K5F is €2.72. The 52 week high of STU:K5F is €5.90 and 52 week low is €2.26.
When is next earnings date of Genenta Science SPA(STU:K5F)?
The next earnings date of Genenta Science SPA(STU:K5F) is 2024-08-30 Est..
Does Genenta Science SPA(STU:K5F) pay dividends? If so, how much?
Genenta Science SPA(STU:K5F) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers